Loading provider…
Loading provider…
Trauma Surgery Physician in Boston, MA
NPI: 1063536944Primary Practice Location
BRIGHAM AND WOMEN'S HOSPITAL
75 Francis St, Boston, MA
Primary Employer
Brigham & Womens Physicians Organization Inc
brighamandwomens.org
HQ Phone
Get M.D. Reza's Phone Numberphone_androidMobile
Get M.D. Reza's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
MA State Medical License
2007 - 2026
DC State Medical License
2003 - 2008
VA State Medical License
2001 - 2006
MD State Medical License
2003 - 2004

American Board of Surgery
Surgery

American Board of Surgery
Surgical Critical Care
George Washington University
Residency • Surgery
2000 - 2007
University of Virginia Medical Center
Fellowship • Surgical Critical Care
2004 - 2005
George Washington University School of Medicine and Health Sciences
smhs.gwu.edu
Medical School
Until 2000
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 99 | 216 |
| 2 | 99223Initial hospital inpatient care, typically 70 minutes per day | 93 | 96 |
| 3 | 99291Critical care delivery critically ill or injured patient, first 30-74 minutes | 76 | 147 |
| 4 | 99239Hospital discharge day management, more than 30 minutes | 26 | 26 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 24 | 31 |
Prolapsed epiploica of the sigmoid colon after total laparoscopic hysterectomy.
Authors: Samadh Ravangard
Journal: JSLS
Authors: Jonathan Gates, Bharti Khurana, Aaron Sodickson
Journal: Radiographics
Risk factors for prolonged need for percutaneous endoscopic gastrostomy (PEG) tubes in adult trauma patients: Experience of a level 1 trauma.
Authors: Lori Gurien, Olubode Olufajo
Publication Date: 2018-12
Lead Sponsor: C. R. Bard
Intervention / Treatment: DEVICE: Xen Matrix AB
Lead Sponsor: Atox Bio Ltd
Intervention / Treatment: DRUG: Placebo, DRUG: Reltecimod 0.5 mg/kg
Lead Sponsor: Atox Bio Ltd
Collaborators: Biomedical Advanced Research and Development Authority
Intervention / Treatment: DRUG: AB103 0.5 mg/kg, OTHER: NaCl 0.9%